Contact: Kathryn Ryan, 914-740-2100, firstname.lastname@example.org
Medication Linked to Improved Reading Skills in Children with Dyslexia
New Rochelle, NY, March 20, 2017
-- A new study of atomoxetine, a drug used to treat attention deficit/hyperactivity disorder (ADHD), was associated with improved reading skills among children 10-16 years of age with either dyslexia alone or with ADHD and dyslexia, compared to placebo. The study results demonstrated improvements in critical reading skills such as vocabulary and coding among children with dyslexia-only, and showed the positive effects of atomoxetine on reading to be independent of the drug's effect on ADHD symptoms in children with ADHD and dyslexia, as reported in Journal of Child and Adolescent Psychopharmacology,
a peer-reviewed journal from Mary Ann Liebert, Inc., publishers
. The article is available free on the Journal of Child and Adolescent Psychopharmacology
Sally Shaywitz, MD, Yale University, and coauthors from the Yale Center for Dyslexia and Creativity (New Haven, CT); Lilly USA, inVentiv Health Clinical, and Indiana University School of Medicine (Indianapolis, IN), AVIDA (Newport Beach, CA), University of California San Francisco, and University of North Carolina, School of Medicine (Chapel Hill, NC), conclude that the improvement in reading measures associated with atomoxetine use in this study helps support proof-of-concept for the ability to improve dyslexia with medication. Atomoxetine is a selective norepinephrine reuptake inhibitor.
"Dyslexia is the most common learning disorder that affects millions of children. This study gives a new potential treatment option that deserves our attention and further study," says Harold S. Koplewicz, MD, Editor-in-Chief of the Journal of Child and Adolescent Psychopharmacology and President of the Child Mind Institute in New York.
About the JournalJournal of Child and Adolescent Psychopharmacology
is an authoritative peer-reviewed journal published ten times per year online with Open Access options and in print. The Journal is dedicated to child and adolescent psychiatry and behavioral pediatrics, covering clinical and biological aspects of child and adolescent psychopharmacology and developmental neurobiology. Complete tables of content and a sample issue may be viewed on the Journal of Child and Adolescent Psychopharmacology website.
About the PublisherMary Ann Liebert, Inc., publishers
is a privately held, fully integrated media company known for establishing authoritative peer-reviewed journals in many promising areas of science and biomedical research, including Cyberpsychology, Behavior, and Social Networking, Games for Health Journal, and Violence and Gender. Its biotechnology trade magazine, GEN (Genetic Engineering & Biotechnology News), was the first in its field and is today the industry’s most widely read publication worldwide. A complete list of the firm’s 80 journals, books, and newsmagazines is available on the Mary Ann Liebert, Inc., publishers
Mary Ann Liebert, Inc. 140 Huguenot St., New Rochelle, NY 10801-5215 www.liebertpub.com
Phone: (914) 740-2100 (800) M-LIEBERT Fax: (914) 740-2101